Logo image of PMN

PROMIS NEUROSCIENCES INC (PMN) Stock Fundamental Analysis

NASDAQ:PMN - Nasdaq - CA74346M4065 - Common Stock - Currency: USD

0.5046  +0.02 (+5.13%)

After market: 0.5049 +0 (+0.06%)

Fundamental Rating

3

Taking everything into account, PMN scores 3 out of 10 in our fundamental rating. PMN was compared to 560 industry peers in the Biotechnology industry. The financial health of PMN is average, but there are quite some concerns on its profitability. PMN has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

PMN had positive earnings in the past year.
PMN had a negative operating cash flow in the past year.
In the past 5 years PMN always reported negative net income.
PMN had a negative operating cash flow in each of the past 5 years.
PMN Yearly Net Income VS EBIT VS OCF VS FCFPMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of PMN (-6.84%) is better than 86.61% of its industry peers.
With an excellent Return On Equity value of -9.86%, PMN belongs to the best of the industry, outperforming 88.39% of the companies in the same industry.
Industry RankSector Rank
ROA -6.84%
ROE -9.86%
ROIC N/A
ROA(3y)-137.72%
ROA(5y)-229.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PMN Yearly ROA, ROE, ROICPMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PMN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PMN Yearly Profit, Operating, Gross MarginsPMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K -40K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for PMN has been increased compared to 1 year ago.
PMN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PMN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PMN Yearly Shares OutstandingPMN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
PMN Yearly Total Debt VS Total AssetsPMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

PMN has an Altman-Z score of -11.94. This is a bad value and indicates that PMN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.94, PMN is doing worse than 77.14% of the companies in the same industry.
There is no outstanding debt for PMN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.94
ROIC/WACCN/A
WACCN/A
PMN Yearly LT Debt VS Equity VS FCFPMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

PMN has a Current Ratio of 3.36. This indicates that PMN is financially healthy and has no problem in meeting its short term obligations.
PMN's Current ratio of 3.36 is on the low side compared to the rest of the industry. PMN is outperformed by 60.36% of its industry peers.
PMN has a Quick Ratio of 3.36. This indicates that PMN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.36, PMN perfoms like the industry average, outperforming 41.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.36
Quick Ratio 3.36
PMN Yearly Current Assets VS Current LiabilitesPMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.01% over the past year.
EPS 1Y (TTM)95.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PMN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.25% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.81%
EPS Next 2Y17.96%
EPS Next 3Y20.62%
EPS Next 5Y9.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PMN Yearly Revenue VS EstimatesPMN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2017 2018 2019 2028 2029 2030 50M 100M 150M 200M 250M
PMN Yearly EPS VS EstimatesPMN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 7.21 indicates a rather cheap valuation of PMN.
98.04% of the companies in the same industry are more expensive than PMN, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.20. PMN is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for PMN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 7.21
Fwd PE N/A
PMN Price Earnings VS Forward Price EarningsPMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PMN Per share dataPMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PMN's earnings are expected to grow with 20.62% in the coming years.
PEG (NY)0.08
PEG (5Y)N/A
EPS Next 2Y17.96%
EPS Next 3Y20.62%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PMN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROMIS NEUROSCIENCES INC

NASDAQ:PMN (5/29/2025, 8:05:54 PM)

After market: 0.5049 +0 (+0.06%)

0.5046

+0.02 (+5.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners29.84%
Inst Owner Change-4.62%
Ins Owners7.3%
Ins Owner Change0%
Market Cap16.50M
Analysts85.71
Price Target7.14 (1314.98%)
Short Float %0.96%
Short Ratio5.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.83%
Min EPS beat(2)-73.27%
Max EPS beat(2)92.93%
EPS beat(4)3
Avg EPS beat(4)180.45%
Min EPS beat(4)-73.27%
Max EPS beat(4)694.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.64%
PT rev (3m)-10.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.69%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 7.21
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.74
P/tB 1.74
EV/EBITDA N/A
EPS(TTM)0.07
EY13.87%
EPS(NY)-0.65
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS0.29
TBVpS0.29
PEG (NY)0.08
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.84%
ROE -9.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-137.72%
ROA(5y)-229.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.36
Quick Ratio 3.36
Altman-Z -11.94
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)6.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.53%
EPS Next Y94.81%
EPS Next 2Y17.96%
EPS Next 3Y20.62%
EPS Next 5Y9.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-58.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-96.21%
EBIT Next 3Y-18.55%
EBIT Next 5Y33.13%
FCF growth 1Y-83.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-83.34%
OCF growth 3YN/A
OCF growth 5YN/A